Skip to main content
. 2021 Jan 4;11(1):3. doi: 10.1038/s41408-020-00405-z

Fig. 2. Development of a CD126-targeted CAR.

Fig. 2

a Schematic representation of CAR constructs used in this study. b CAR-T cell-mediated killing of RPMI and a derivative population with suppressed CD126 expression using shRNA (RPMI-CD126 shRNA) both expressing luciferase incubated with CAR-T cells at different effector-to-target ratios (n = 12). c Cell killing of K562 and K562 that express CD126 (K562 CD126 OE) and luciferase with CAR-T cells at different effector-to-target ratios (n = 12). Data are mean ± standard deviation. Two-way ANOVA and multiple comparison test. n.s. Not significant. ****P < 0.0001.